|
KMID : 1151620170020010021
|
|
Journal of Retina
2017 Volume.2 No. 1 p.21 ~ p.26
|
|
|
One-year Treatment Outcome of Intravitreal Aflibercept for Neovascular Age-related Macular Degeneration with Good Initial Visual Acuity
|
|
Kim Jae-Hui
Kim Jee-Taek
Oh Jong-Hyun
Shin Kyung-Hoon
Nam Ki-Yup
|
|
|
Abstract
|
|
|
Purpose: To evaluate the effect of intravitreal aflibercept injection on wet age related macular degeneration (wet-AMD) patients with relatively good visual acuity (VA) of more than 0.5.
Methods: We retrospectively reviewed medical records of patients who were diagnosed with wet-AMD and treated with intravitreal aflibercept injection. Only patients with a best corrected VA (BCVA) of more than 0.5 at initial diagnosis and who were followed up more than 12 months were enrolled. BCVA (logarithm of minimal angle of resolution [logMAR] conversion) and central macular thickness (CMT) after 3 loading treatments and at 12 months were investigated and compared with those at initial visit. Also, recurrences and complications were investigated.
Results: 15 eyes of 15 patients were enrolled. The average number of injections was 4.9 ± 1.3. Mean BCVA at initial diagnosis, 3 months and 12 months was 0.25 ± 0.08, 0.19 ± 0.11, 0.19 ± 0.11, respectively, and there were no statistically significant differences between initial visit and 3, 12 months. 5 eyes (33.3%) showed visual improvement of more than 2 logMAR VA and 9 eyes (60.0%) had no obvious VA change. In 1 eye, VA worsened by more than 2 logMAR VA. Mean CMT at initial diagnosis, 3 months and 12 months was 394.8 ± 115.5 μm, 266.5 ± 84.1 μm, 284.5 ± 64.2 μm, respectively, and the CMT difference between at initial visit and 3, 12 months was statistically significant (p =0.001, 0.017). There were no complications associated with intravitreal aflibercept injection.
Conclusions: Intravitreal aflibercept injection in patients with relatively good VA showed good results for vision, and in most patients, vision was improved or preserved for 12 months.
|
|
|
KEYWORD
|
|
|
Aflibercept, Age related macular degeneration, Intravitreal injection
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|